Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 3/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2838106 | 0.79 | ALOX5 (0.53) | ALOX5LMNA | |
| SCHEMBL5949584 | 0.78 | ALOX5 (0.53) | CYP2D6ALOX5KMT2AMEN1ALDH1A1 | |
| SCHEMBL7593804 | 0.78 | ALOX5 (0.53) | CYP2D6ALOX5KMT2AMEN1ALDH1A1 | |
| SCHEMBL7908361 | 0.74 | MMP2 (0.43) | CYP2D6SRCALOX5LMNAKMT2A | |
| SCHEMBL6176307 | 0.74 | MMP2 (0.46) | CYP2D6ALOX5LMNAKMT2AMEN1 | |
| SCHEMBL8002766 | 0.73 | ALDH1A1 (0.49) | CYP2D6LMNAKMT2AMEN1ALDH1A1 | |
| SCHEMBL8305232 | 0.72 | SRC (0.42) | CYP2D6SRCALOX5LMNAMAPK1 | |
| SCHEMBL9575320 | 0.70 | CYP2D6 (0.42) | CYP2D6SRCLMNAMAPK1KMT2A | |
| SCHEMBL22575939 | 0.69 | KDM4E (0.46) | ALOX5LMNAKMT2AMEN1ALDH1A1 | |
| SCHEMBL8132433 | 0.67 | SCN4A (0.36) | CYP2D6LMNAKMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2139850-B1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC (CA) | 2018-09-12 | — | — | EP | disclosed |
| US-9096565-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2015-08-04 | — | — | US | disclosed |
| US-9096565-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2015-08-04 | — | — | US | disclosed |
| US-9096565-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2015-08-04 | — | — | US | disclosed |
| CN-101679220-A | Histone deacetylase inhibitor | METHYLGENE INC | 2010-03-24 | — | — | CN | disclosed |
| EP-2139850-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2010-01-06 | — | — | EP | disclosed |
| US-20090181943-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2009-07-16 | — | — | US | disclosed |
| US-20090181943-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2009-07-16 | — | — | US | disclosed |
| US-20090181943-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2009-07-16 | — | — | US | disclosed |
| WO-2008122115-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008122115-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181943-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC11, HDAC3 | CYP2D6 986/4885SRC 2547/4885ALOX5 2866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.